Illumina introduces the MiSeq i100 Series: its simplest, fastest benchtop sequencers
Illumina has unveiled its MiSeq i100 Series of sequencing systems, designed to make next-generation sequencing (NGS) more accessible. The new benchtop instruments, MiSeq i100 and MiSeq i100 Plus Systems, offer unparalleled speed and simplicity for labs.
Key features include:
- Room-temperature reagent storage and shipping
- 85% reduction in packaging waste
- Run times as fast as four hours
- Cost-effective consumables
- 18 proven end-to-end workflows across 10 applications
- Simplified operations for various experience levels
The MiSeq i100 Series builds on the legacy of the original MiSeq System, incorporating technology from the NovaSeq X Series. It offers flexible output capabilities, with the MiSeq i100 Plus System providing 100 million single-end reads per run, and the MiSeq i100 System offering 25 million.
Early access testing has received positive feedback from customers, highlighting the instrument's speed, flexibility, and ease of use. The MiSeq i100 will be available globally in 2025.
Illumina ha svelato la sua Serie MiSeq i100 di sistemi di sequenziamento, progettata per rendere il sequenziamento di nuova generazione (NGS) più accessibile. I nuovi strumenti da banco, Sistemi MiSeq i100 e MiSeq i100 Plus, offrono velocità e semplicità senza pari per i laboratori.
Le principali caratteristiche includono:
- Stoccaggio e spedizione dei reagenti a temperatura ambiente
- Riduzione dell'85% dei rifiuti di imballaggio
- Tempi di esecuzione rapidi fino a quattro ore
- Consumi convenienti
- 18 flussi di lavoro end-to-end collaudati per 10 applicazioni
- Operazioni semplificate per vari livelli di esperienza
La Serie MiSeq i100 si basa sull'eredità del sistema MiSeq originale, incorporando la tecnologia della Serie NovaSeq X. Offre capacità di output flessibili, con il Sistema MiSeq i100 Plus che fornisce 100 milioni di letture single-end per corsa, e il Sistema MiSeq i100 che offre 25 milioni.
I test di accesso anticipato hanno ricevuto feedback positivi dai clienti, evidenziando la velocità, la flessibilità e la facilità d’uso dello strumento. Il MiSeq i100 sarà disponibile a livello globale nel 2025.
Illumina ha presentado su Serie MiSeq i100 de sistemas de secuenciación, diseñada para hacer que la secuenciación de próxima generación (NGS) sea más accesible. Los nuevos instrumentos de mesa, Sistemas MiSeq i100 y MiSeq i100 Plus, ofrecen una velocidad y simplicidad incomparables para los laboratorios.
Las características clave incluyen:
- Almacenamiento y envío de reactivos a temperatura ambiente
- Reducción del 85% en residuos de embalaje
- Tiempos de ejecución de hasta cuatro horas
- Consumibles rentables
- 18 flujos de trabajo de extremo a extremo probados en 10 aplicaciones
- Operaciones simplificadas para varios niveles de experiencia
La Serie MiSeq i100 se basa en el legado del sistema MiSeq original, incorporando tecnología de la Serie NovaSeq X. Ofrece capacidades de producción flexibles, con el Sistema MiSeq i100 Plus que proporciona 100 millones de lecturas de extremo único por ejecución, y el Sistema MiSeq i100 que ofrece 25 millones.
Las pruebas de acceso anticipado han recibido comentarios positivos de los clientes, destacando la velocidad, flexibilidad y facilidad de uso del instrumento. El MiSeq i100 estará disponible globalmente en 2025.
일루미나가 차세대 시퀀싱(NGS)을 보다 접근 가능하게 만들기 위해 설계된 MiSeq i100 시리즈 시퀀싱 시스템을 공개했습니다. 새로운 벤치탑 기기인 MiSeq i100 및 MiSeq i100 Plus 시스템은 실험실을 위한 비할 데 없는 속도와 단순성을 제공합니다.
주요 특징으로는:
- 실온에서의 시약 저장 및 배송
- 포장 폐기물 85% 감소
- 최대 4시간의 빠른 실행 시간
- 비용 효율적인 소모품
- 10개 응용 프로그램에 걸쳐 18개의 검증된 엔드투엔드 워크플로우
- 다양한 경험 수준을 위한 단순화된 작업 운영
MiSeq i100 시리즈는 기존의 MiSeq 시스템의 유산을 바탕으로 하며, NovaSeq X 시리즈의 기술을 통합합니다. MiSeq i100 Plus 시스템은 실행당 1억 개의 단일 종단 읽기를 제공하고, MiSeq i100 시스템은 2,500만 개를 제공합니다.
조기 접근 테스트는 고객으로부터 긍정적인 피드백을 받았으며, 기기의 속도, 유연성 및 사용 편리성을 강조했습니다. MiSeq i100은 2025년에 전 세계적으로 출시될 예정입니다.
Illumina a dévoilé sa Série MiSeq i100 de systèmes de séquençage, conçus pour rendre le séquençage de nouvelle génération (NGS) plus accessible. Les nouveaux instruments de table, Systèmes MiSeq i100 et MiSeq i100 Plus, offrent une rapidité et une simplicité sans précédent pour les laboratoires.
Les principales caractéristiques incluent :
- Stockage et expédition des réactifs à température ambiante
- Réduction de 85 % des déchets d'emballage
- Temps d'exécution aussi rapide que quatre heures
- Consommables économiques
- 18 workflows de bout en bout éprouvés sur 10 applications
- Fonctionnements simplifiés pour différents niveaux d'expérience
La Série MiSeq i100 s'appuie sur l'héritage du système MiSeq original, intégrant la technologie de la Série NovaSeq X. Elle offre des capacités de sortie flexibles, le Système MiSeq i100 Plus fournissant 100 millions de lectures single-end par course, et le Système MiSeq i100 offrant 25 millions.
Les tests d'accès anticipé ont reçu des commentaires positifs des clients, soulignant la vitesse, la flexibilité et la facilité d'utilisation de l'instrument. Le MiSeq i100 sera disponible mondialement en 2025.
Illumina hat seine MiSeq i100 Serie von Sequenzierungssystemen vorgestellt, die darauf ausgelegt sind, die Next-Generation-Sequencing (NGS) zugänglicher zu machen. Die neuen Tischgeräte, MiSeq i100 und MiSeq i100 Plus Systeme, bieten unvergleichliche Geschwindigkeit und Einfachheit für Laboratorien.
Zu den wichtigsten Merkmalen gehören:
- Lagerung und Versand von Reagenzien bei Raumtemperatur
- 85% weniger Verpackungsmüll
- Laufzeiten von bis zu vier Stunden
- Kostengünstige Verbrauchsmaterialien
- 18 erprobte End-to-End-Workflows über 10 Anwendungen
- Vereinfachte Abläufe für verschiedene Erfahrungslevels
Die MiSeq i100 Serie baut auf dem Erbe des ursprünglichen MiSeq Systems auf und integriert Technologie aus der NovaSeq X Serie. Sie bietet flexible Ausgabefähigkeiten, wobei das MiSeq i100 Plus System pro Lauf 100 Millionen Einzelend-Lesungen und das MiSeq i100 System 25 Millionen bietet.
Frühe Testzugänge erhielten positive Rückmeldungen von den Kunden, die die Geschwindigkeit, Flexibilität und Benutzerfreundlichkeit des Instruments hervorheben. Der MiSeq i100 wird 2025 weltweit verfügbar sein.
- Introduction of new MiSeq i100 Series with improved speed and simplicity
- Room-temperature reagent storage and shipping, enabling on-demand sequencing
- 85% reduction in packaging waste, supporting sustainability efforts
- Faster run times (as quick as 4 hours) compared to previous models
- Cost-effective consumables for more affordable sequencing
- 18 proven end-to-end workflows across 10 applications
- Simplified operations suitable for various levels of sequencing experience
- None.
Insights
The introduction of the MiSeq i100 Series represents a significant advancement in benchtop sequencing technology. Key innovations include:
- Room-temperature reagent storage and shipping, eliminating the need for cold chain logistics
- Faster run times (up to 4x faster than previous MiSeq systems)
- Simplified workflows suitable for users with varying levels of NGS expertise
- Cost-effective consumables for more affordable sequencing
- Reduced environmental impact with 85% less packaging waste
These improvements address critical pain points in the NGS market, potentially expanding Illumina's customer base to include smaller labs and those new to sequencing. The system's flexibility and ease of use could drive increased adoption of NGS technology across various applications, from microbiology to oncology.
For investors, this product launch signals Illumina's continued innovation and market leadership in the sequencing space. The MiSeq i100 Series could help Illumina maintain its competitive edge and potentially capture new market segments, particularly in settings where speed, simplicity and cost-effectiveness are crucial.
The launch of the MiSeq i100 Series is strategically significant for Illumina and the broader NGS market. This product addresses several key market trends:
- Democratization of sequencing: By simplifying workflows and reducing costs, Illumina is making NGS more accessible to a wider range of labs.
- Demand for faster results: The rapid turnaround time (as fast as 4 hours) caters to time-sensitive applications in clinical and research settings.
- Sustainability focus: The reduced packaging waste and elimination of cold chain requirements align with growing environmental concerns in the scientific community.
The MiSeq i100 Series could potentially expand Illumina's total addressable market by attracting new customers who previously found NGS too complex or expensive. This move also helps Illumina defend its market position against emerging competitors in the benchtop sequencing space.
While the full financial impact won't be clear until after the 2025 launch, this product line has the potential to drive significant revenue growth for Illumina, especially if it can capture market share in emerging applications like infectious disease surveillance and targeted oncology panels.
Designed to make next-generation sequencing accessible to more labs
With room-temperature kit storage and shipping, Illumina's newest sequencers remove barriers to enable more insights and discoveries
The two new benchtop instruments, MiSeq i100 and MiSeq i100 Plus Systems, will empower customers to unlock powerful insights through an affordable, comprehensive solution that is simple to understand and use, even for those with limited NGS expertise. Room-temperature storage and shipping enable labs to sequence on demand, with no delays for thaw time, and same-day sample-to-analysis.
"Our customers told us they need a faster, smaller, and easy-to-use instrument, and that's what we're delivering with the MiSeq i100," said Jacob Thaysen, PhD, CEO of Illumina. "Whether you are an established next-generation sequencing lab, or looking to start sequencing for the first time, our latest benchtop instrument adds the plug-and-play flexibility that today's labs are seeking."
The MiSeq i100 Series builds on the legacy of the original benchtop MiSeq System, which Illumina customers have used since 2011 to power a host of genomic discoveries. Completely redesigned and incorporating the groundbreaking technology and chemistry of the NovaSeq™ X Series, the MiSeq i100 will help to fuel the next era of genomics growth and discovery.
Key technology enhancements
The MiSeq i100 Series brings Illumina's powerful XLEAP-SBS™ chemistry innovation even further—for the first time, harnessing the potential of room-temperature storage and shipping, which provides customers greater flexibility in how they plan and execute their projects while reducing their environmental impact. It offers flexible output capabilities and comes in two configurations: the MiSeq i100 Plus System has the full 100 million single-end reads per run, and the MiSeq i100 System has a maximum of 25 million single-end reads per run. Key features include:
- Room-temperature shipping and storage for reagents: Eliminating the cold chain and allowing for greater flexibility to sequence on demand without the need to thaw reagents, which is critical for running urgent samples
- Sustainability: An
85% reduction in packaging waste compared to the MiSeq System supports a lower carbon footprint - Speed: Dramatic reduction in run times: as fast as four hours, with same-day results (4× faster than MiSeq)
- Cost efficiency: Cost-effective consumables enable more affordable sequencing
- Turnkey workflows: 18 proven end-to-end workflows across 10 applications
- Simplicity: Simpler, streamlined operations for various levels of sequencing experience
Push-button workflows on MiSeq i100 are available for small whole-genome sequencing for microbiology and targeted NGS panels for both infectious disease and oncology. Workflows provide metrics either directly on the instrument or via cloud-based DRAGEN™ genomic data analysis, minimizing the need for bioinformatics expertise.
"The MiSeq i100 symbolizes Illumina's commitment to delivering total systems with complete workflows that allow our customers to accomplish more," said Steve Barnard, PhD, chief technology officer of Illumina. "With its enhanced speed, simplicity, scalability, and quality–and its intuitive user experience–the MiSeq i100 sets a new standard for benchtop sequencing."
Customer reactions
Illumina conducted early access testing of MiSeq i100 with customers around the world. Geneviève DonPierre, team leader of NGS Sequencing at Génome
Génome Québec is a nonprofit organization that provides genomic services for researchers in the academic and industrial fields of 45 countries. DonPierre noted the importance of room temperature storage for her lab: "It really helps the planning for the sequencing run. We don't have to think two days before to get a kit out of the freezer. So it really is a game changer to have kits stored at room temperature."
Tim Roloff Handschin, PhD, co-leader of Microbial Genomics (NGS) at the Institute for Medical Microbiology at the University of
"We can start two runs on the same day and thereby increase our sample flow massively. And given that the reagents are shipped at room temperature, we don't need to wait for the cartridges to thaw," Roloff said. "We can just launch a run whenever we're ready with a new pool and there is no planning needed upfront. This gives us great flexibility, and this can provide new possibilities to develop new tests."
The new instrument was unveiled during a virtual customer event; a replay may be viewed here. The MiSeq i100 will be available to ship globally in 2025. For more information, visit the website.
Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing, manufacturing, and launching new products and services; (ii) our ability to manufacture robust instrumentation and consumables; (iii) customer uptake of, and satisfaction with new products and services; and (iv) the speed and scale of new product adoption by customers, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.
About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.
Contacts
Investors:
Salli Schwartz
858-291-6421
IR@illumina.com
Media:
Christine Douglass
PR@illumina.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-introduces-the-miseq-i100-series-its-simplest-fastest-benchtop-sequencers-302270917.html
SOURCE Illumina, Inc.
FAQ
When will the Illumina MiSeq i100 Series be available for purchase (ILMN)?
What are the key features of the new Illumina MiSeq i100 Series (ILMN)?
How does the MiSeq i100 Series differ from the original MiSeq System (ILMN)?
What are the output capabilities of the MiSeq i100 and MiSeq i100 Plus Systems (ILMN)?
